'Braf mutations' diaporamas de présentation

Updates in Community Oncology 2011: A Focus on Melanoma

Updates in Community Oncology 2011: A Focus on Melanoma. This program is supported by educational grants from Bristol-Myers Squibb, Genentech BioOncology, and Merck. About These Slides. Our thanks to the presenters who gave permission to include their original data

722 views • 59 slides

717 views • 48 slides

New Frontiers in Pathology

New Frontiers in Pathology. Case #7 August 3, 2012 Michael H. Roh, MD, PhD University of Michigan Health System. Disclosure Information. The speaker has no relationship representing a possible conflict of interest with respect to the content of this presentation. History.

577 views • 43 slides

Cracow, 13th of September, 2018 Prof. Ewa ?. St?pie?

373 views • 37 slides

ASCO Annual Meeting 2012

ASCO Annual Meeting 2012. PHASE II STUDY OF PANITUMUMAB (P) IN COMBINATION WITH FOLFOXIRI AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): HIGH ACTIVITY IN MOLECULARLY SELECTED PATIENTS (PTS).

387 views • 20 slides

Detection of BRAF Mutations in Tumour and Serum of Patients with Advanced Melanoma

305 views • 14 slides

Kefford R et al. Proc ASCO 2010;Abstract 8503.

Phase 1/2 Study of GSK2118436, a Selective Inhibitor of Oncogenic Mutant BRAF Kinase in Patients with Metastatic Melanoma and Other Solid Tumors. Kefford R et al. Proc ASCO 2010;Abstract 8503. Introduction.

306 views • 12 slides